减肥药新秀银诺医药，上市首日高开超280%

Group 1 - The core product of the company, Isu-Paglutide α, has been approved by the National Medical Products Administration and was commercialized in February 2023, making it the first domestically developed long-acting GLP-1 drug with independent intellectual property rights [3] - The company experienced a significant market response upon its IPO, with a subscription rate of 5341.66 times, raising approximately 6.347 billion HKD from the issuance of 36.56 million shares at a price of 18.68 HKD per share [1] - The company plans to allocate approximately 90% of the funds raised from the IPO to ongoing and planned clinical trials, as well as the commercialization of Isu-Paglutide α, including further clinical research for indication expansion [1] Group 2 - The company was established in 2014 and focuses on developing treatments for obesity, overweight, and metabolic dysfunction-related fatty liver disease (MASH) [2] - The company has not yet achieved profitability, with projected losses of 733 million CNY in 2023, 175 million CNY in 2024, and 97.88 million CNY by May 2025, while generating revenue of 38.1 million CNY from Isu-Paglutide α sales [3] - The company has conducted four rounds of financing from 2020 to 2024, raising a total of approximately 1.558 billion CNY, all directed towards the research and development of Isu-Paglutide α [1][2]